Losartan
Established medicineAlso known as Arbli, Cozaar, Hyzaar, Hydrochlorothiazide-Losartan+1 more
Arbli, Cozaar, Hyzaar, Hydrochlorothiazide-Losartan, Losartan Potassium.
Recent clinical, regulatory, research and industry developments relating to this drug.
Losartan for Diffuse Myocardial Fibrosis in Sickle Cell Disease: A Prospective, Phase II Study.
The Effect of Losartan on Cephalexin
Investigation of the Effectiveness of Exercise and Anti-Fibrotic Approaches in Frozen Shoulder
Effects of losartan and allopurinol on cardiorespiratory regulation in obstructive sleep apnoea.
Losartan for the nephropathy of sickle cell anemia: A phase-2, multicenter trial.
Evidence confidence
How strongly the incorporated evidence supports specific clinical claims about this treatment. A confidence figure is a current summary of evidence strength, not a permanent verdict.
High point estimate, but substantial uncertainty remains.
Confidence has a moderate point estimate but a wide uncertainty band — the evidence base is still thin.
Profile
Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.
Clinical trials
The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.
Late-stage studies
Phase III+ trials still open or recently active — where late-stage evidence is being generated.
Recent completions
Trials that read out recently, adding to the completed evidence base.
Research activity
Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.
Major research themes2
Journals, researchers & institutions
- American journal of hematology1
- Clinical journal of the American Society of Nephrology : CJASN1
- Clinical science (London, England : 1979)1
- Diabetes1
- EClinicalMedicine1
- Experimental physiology1
- Abate NI1
- Ackerman HC1
- Albu JB1
- Aliota MT1
- Azuma K1
- Beckman K1
- Bellolio F1
- Bennett PH1
- Akron Children's Hospital1
- and Blood Institute1
- Arkansas Children's Hospital1
- Aurora BayCare Medical Center1
- Brigham and Women's Hospital1
- Cancer and Blood Diseases Institute1
- RxNorm (U.S. National Library of Medicine) — drug identity
- ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
- Europe PMC — research literature
- ClinicalTrials.gov — clinical trials